Kevin Kalinsky, MD, on HR-Positive HER2-Negative Breast Cancer: Endocrine Therapy and Chemotherapy
Kevin Kalinsky, MD, of the Winship Cancer Institute at Emory University, discusses updated phase III results from the SWOG S1007 (RxPONDER) study of women with one to three positive lymph nodes, and hormone receptor–positive, HER2-negative breast cancer. The data showed that postmenopausal women with recurrence scores (RS) from 0 to 25 continue not to benefit from adjuvant chemotherapy, whereas premenopausal women with a RS from 0 to 25 did benefit from the addition of chemotherapy to endocrine therapy (Abstract GS2-07).